ATM Programs
The Company enters into at-the-market (“ATM”) programs through which the Company, from time to time, sells shares of common stock and/or enters into forward sale agreements.
| | | | | | |
| | Program Size | | | | Net Proceeds |
Program Year | | ($ million) | | Shares Issued | | ($ million) |
2020 | * | $400.0 | | 3,334,056 | | $209.5 |
2021 | * | $500.0 | | 5,453,975 | | $379.1 |
2022 | * | $750.0 | | 10,217,973 | | $670.2 |
2024 | | $1,000.0 | | - | | - |
* ATM Programs have been terminated and no future issuance will occur under them.
2024 ATM Program
In February 2024, the Company entered into a $1.00 billion ATM program (the “2024 ATM Program”). As of March 31, 2024, the Company had not entered into any forward sale agreements under the 2024 ATM Program.
The previous $750.0 million ATM program (the “2022 ATM Program”) was terminated simultaneously with the establishment of the 2024 ATM Program. As a result, no future issuances will occur under the 2022 ATM Program.
2022 ATM Program
In September 2022, the Company entered into the 2022 ATM Program.
Since inception of the 2022 ATM Program and through adoption of the 2024 ATM Program on February 16, 2024, the Company entered into forward sale agreements to sell an aggregate of 10,217,973 shares of common stock under the 2022 ATM Program, for anticipated net proceeds of $670.2 million. Through December 31, 2023, the Company settled 6,363,359 shares of these forward sale agreements for net proceeds of approximately $433.4 million, after deducting fees and expenses. During the three months ended March 31, 2024, the Company did not settle any of the remaining outstanding shares. The Company is required to settle the remaining outstanding shares of common stock under the 2022 ATM Program by January 2025.
As of March 31, 2023, under the 2022 ATM Program, the Company had entered into forward sale agreements to sell an aggregate of 4,350,232 shares of common stock, for anticipated proceeds of $300.6 million. Through December 31, 2022, the Company settled 245,591 shares of these forward sale agreements for net proceeds of approximately $18.1 million, after deducting fees and expenses. During the three months ended March 31, 2023, no forward sale agreements were entered and no shares were settled under the 2022 ATM Program.
Note 7 – Dividends and Distribution Payable
During the three months ended March 31, 2024 and 2023, the Company declared monthly dividends of $0.247 and $0.240, respectively, per common share. Holders of Operating Partnership Common Units are entitled to an equal distribution per Operating Partnership Common Unit held. The dividends and distributions payable for January and February were paid during the three months ended March 31, 2024 and 2023, while the March dividends and distributions were recorded as liabilities on the condensed consolidated balance sheets at March 31, 2024 and 2023. The March 2024 and 2023 dividends per common share and distributions per Operating Partnership Common Units were paid on April 12, 2024 and April 14, 2023, respectively.
During the three months ended March 31, 2024 and 2023, the Company declared monthly dividends on the Series A Preferred Shares in the amount of $0.08854, per Depositary Share. The dividends payable for January and February were paid during the three months ended March 31, 2024 and 2023, while the March dividends and distributions were recorded as a liability on the condensed consolidated balance sheet at March 31, 2024 and 2023. The March 2024 and 2023 dividends per Depository Share were paid on April 1, 2024 and April 3, 2023, respectively.